Wegovy carries roughly five times the risk of ischemic optic neuropathy compared with Ozempic, BMJ Ophthalmology analysis

Anyone using Wegovy for weight loss carries roughly five times the risk of ischemic optic neuropathy compared with Ozempic users, according to a new analysis in the British Journal of Ophthalmology. Wegovy showed the strongest signal among semaglutide drugs, with men carrying abo

Anyone using Wegovy for weight loss carries roughly five times the risk of ischemic optic neuropathy compared with Ozempic users, according to a new analysis in the British Journal of Ophthalmology. Wegovy showed the strongest signal among semaglutide drugs, with men carrying about three times the risk women did. Both drugs come from Novo Nordisk $NVO.